Drugs / engineered red blood cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05707325 | Jan 2023 → Dec 2025 overdue | cancer, hematopoietic and lymphoid cell neoplasm | Westlake Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | engineered red blood cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05707325 ↗ |
| Modality | Cell therapy | “novel red blood cell-based therapy” NCT05707325 ↗ |